Boston, United States
1910 Genetics is a pioneering biotechnology company established in 2018, setting itself apart by utilizing a multimodal AI platform to advance both small and large molecule drug discovery. The company integrates AI with three proprietary datasets—computational, wet lab proxy biological, and wet lab ground truth biological data—designed to deliver innovative drug candidates and software solutions to top-tier pharma and tech partners.
Headquartered in the United States, 1910 Genetics focuses on enhancing treatments for neurological, autoimmune diseases, and cancer, advancing an internal pipeline with significant potential. The company garners substantial backing from major investors such as M12 - Microsoft's Venture Fund, Playground Global, Sam Altman, Y Combinator, FoundersX Ventures, and Scientia Ventures. Most recently, the company secured a Venture Round investment on 31 October 2024, led by Accenture Ventures, signaling confidence in their innovative approach and future growth trajectory.
